Clinical Research Directory

Inclusion Criteria: * 1.Age ≥18 years old, both male and female are acceptable. * 2\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards: 1. always has not received the immune therapy, 2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \> 3 months, withdrawal time \> 3 months) 3. never used anlotinib, * 3\. ECOG: 0 \~ 2; * 4 . The expected lifetime 12 weeks or more; * 5\. Major organs function normal Exclusion Criteria: * 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders; * 2.With known the special ripley sheet resistance, etoposide contraindication; * 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.